No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma
the ONA take:
According to initial results presented this week at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, the use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma who are at a high risk of recurrence.
The phase 3 trial conducted by the ECOG-ACRIN Cancer Research Group is the first and largest study reporting on the efficacy of sunitinib or sorafenib in patients who have undergone surgery to remove the kidney tumor.
"Unfortunately we found that the use of sunitinib or sorafenib in this setting did not reduce the incidence of recurrence as compared to standard care," said lead researcher Naomi B. Haas, MD, from the University of Pennsylvania's Abramson Cancer Center in Philadelphia.
For the international, phase III study, researchers enrolled 1,943 patients considered at high risk for recurrence following surgery to remove a kidney tumor and randomly assigned them to receive sorafenib, sunitinib, or placebo for 1 year.
Results of the study showed a median progression-free survival of 5.6 years for those treated with sunitinib compared with 5.6 years for those treated with sorafenib and 5.7 years for those who received placebo.
Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|